Related Experiment Videos
Modification of the enkephalin "message" with an artificial polycationic C-terminus.
A R Jacobson1, S W Tam, L M Sayre
1Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106-7078.
Journal of Medicinal Chemistry
|September 1, 1991
Summary
Researchers explored opioid receptor interactions by adding cationic fragments to opioid peptides. The modified peptides showed weak binding and marginal activity, suggesting the hypothesized coulombic interaction may not be a primary factor in receptor recognition.
Area of Science:
- Pharmacology and Medicinal Chemistry
- Neuroscience and Receptor Binding Studies
Background:
- Prodynorphin-derived opioid peptides feature C-terminal basic residues critical for kappa-opioid receptor activity and selectivity.
- A hypothesis suggests these polycationic C-terminal "tails" may interact electrostatically with polyanionic receptor domains.
Purpose of the Study:
- To investigate the role of coulombic interactions in opioid receptor recognition.
- To synthesize and test novel opioid peptide analogs with attached cationic fragments.
Main Methods:
- Attachment of achiral, peptide-like cationic fragments to the C-terminus of the opioid peptide Tyr-Gly-Gly-Phe.
- Assessment of ligand binding affinity to various opioid receptor types using guinea pig brain membranes.
- Evaluation of pharmacologic activity in the guinea pig ileum assay.
Main Results:
- The synthesized compounds exhibited weak binding affinities across different opioid receptor types.
- Pharmacologic activities in the guinea pig ileum were marginal, indicating limited functional effects.
- The tested ligand designs did not strongly support the hypothesized coulombic interaction model.
Conclusions:
- The study suggests that the hypothesized coulombic interaction between polycationic peptide tails and polyanionic receptor domains may not be a major determinant of opioid receptor recognition.
- Alternative ligand designs or other interaction mechanisms might be more critical for achieving high affinity and selectivity for kappa-opioid receptors.